



TSC ALERT

Edited by Vicky Holets Whittemore, Ph.D. & Cheryl Dunigan, Ph.D.

August 16, 2003

Welcome to the August edition of *TSC Alert* – an online research newsletter for individuals interested in Tuberous Sclerosis Complex (TSC) research and clinical care. This online newsletter contains information of interest to the TSC research and health care community. Please forward this newsletter to colleagues who are interested in TSC. To be added/deleted to/from the mailing list for *TSC Alert* and/or to submit information for the September 2003 *TSC Alert* contact: Vicky.Whittemore@tsalliance.org

Table of Contents

[Clicking on one of the headings takes you directly to that section of TSC Alert]

GRANT ANNOUNCEMENTS:	1
NIH ANNOUNCEMENTS:	4
RESEARCH RESOURCES:	4
TSC TISSUE AVAILABILITY:	4
CLINICAL TRIALS/STUDIES:	5
NEW TSC PUBLICATIONS:	6
LEGISLATIVE UPDATE:	8
NEWS:	9
CONFERENCES:	9
ARCHIVED ISSUES OF TSC ALERT:	10

GRANT ANNOUNCEMENTS:

J.S. McDONNELL FOUNDATION

Collaborative Activity Awards

No specific deadline for submission of applications.

The J.S. McDonnell Foundation offers Collaborative Activity Awards to initiate interdisciplinary discussions on problems or issues, to help launch interdisciplinary research networks, or to fund communities of researchers/practitioners dedicated to developing new methods, tools, and applications of basic research to applied problems. In each case the focus of the collaborative activity must meet the program guidelines as described.

NOTE: Collaborative awards will not be awarded in support of large, program-project style research proposals. Applicants requesting funds to support innovative research projects involving several laboratories should consider submitting one or more applications to the 21st Century

Research Awards. Applicants can request that proposals from the individual laboratories be "bundled", meaning that the applications will be reviewed and considered for funding as a single entity.

<http://www.jsmf.org/apply/collaborative/>

THE LAM FOUNDATION

Application deadline: September 1st

The LAM Foundation is offering postdoctoral fellowships for the study of the cellular and molecular basis of the abnormal smooth muscle proliferation that occurs in the disease Lymphangioliomyomatosis (LAM). For additional information, contact:

The LAM Foundation

Sue Byrnes, Director

10105 Beacon Hills Drive, Cincinnati, OH 45241

Telephone: 513-777-6889

FAX: 513-777-4109

E-mail: lam@one.net Web site: <http://lam.uc.edu>

BURROUGHS WELLCOME FUND – CAREER AWARDS IN THE BIOMEDICAL SCIENCES

Application deadline: October 1, 2003

Career awards provide \$500,000 for five years to bridge the advanced postdoctoral years and the first years of faculty service. These awards are intended to foster the development of biomedical researchers who are early in their careers and help them make the critical transition to becoming independent investigators. Candidates must be citizens or permanent residents of the U.S. or Canada at the time of application. Applications must be submitted by U.S. or Canadian degree-granting institutions on behalf of individual candidates. Candidates must have completed at least 12 months but not more than 48 months of postdoctoral research training by the application deadline. Approximately half of the awards will go to researchers with a Ph.D. degree and half to those with an M.D. or M.D.-Ph.D. degree, although there is no requirement to this effect.

http://www.bwfund.org/programs/biomedical_sciences/career_background.html

PEW LATIN AMERICA FELLOWS PROGRAM IN THE BIOMEDICAL SCIENCES

Application deadline is October 1, 2003

The Pew Latin America Fellows Program in the Biomedical Sciences provides support for young scientists from Latin America for post-doctoral training in the U.S. An award of \$50,000 will be provided as a salary stipend for the fellow during the period of training (2 years) and will be administered by the sponsoring U.S. institution. The sponsoring institution is required to supplement the salary stipend with at least \$5,000 a year and to provide full medical benefits for the fellow. Following the two year fellowship, the Program will issue an additional \$35,000 award to the sponsoring institution to purchase equipment and supplies for the fellow to establish a laboratory in his or her home country. Additional information and applications may be obtained at: <http://www.pewlatinfellows.com>

NINDS EXPLORATORY/DEVELOPMENTAL GRANTS FOR TRANSLATIONAL RESEARCH

The NINDS uses the Exploratory/Developmental (R21) Grants to provide research support for new research projects in areas of high relevance to the mission of the [NINDS](#). Applicants may request a project period of up to two years with a combined budget for direct costs of up to \$275,000 for the two year period. For example, the applicant may request \$100,000 in the first year and \$175,000 in the second year. The request should be tailored to the needs of the

project. Normally, no more than \$200,000 may be requested in any single year. See also full program announcement NIH Exploratory/Developmental Research Grant Award (R21): [PA-03-107](#)

As an Exploratory/Developmental mechanism, the R21 Grant is intended to support projects that: 1) assess the feasibility of a novel avenue of investigation 2) involve high risk experiments that could lead to a breakthrough in a particular field or 3) demonstrate the feasibility of new technologies that could have major impact in a specific area. To be eligible for consideration, proposals must be distinct from those traditionally submitted through the R01 mechanism. For example, projects designed to produce incremental advances in knowledge in a well-established area will not be considered. Proposals submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.

NINDS also supports R21 Exploratory/Developmental Projects in Translational Research to support research projects intended to discover potential targets for therapeutic intervention, to identify candidate therapeutics, or to develop assays, animal models, devices, or technologies for screening or developing therapeutics. Such projects, if successful, should lead directly to a therapy development project for a particular neurological disorder. For additional Information, see: [PAR-02-138.html](#)

CENTERS OF EXCELLENCE IN ELSI RESEARCH (CEER) REQUEST FOR APPLICATIONS

The Ethical, Legal, and Social Implications (ELSI) Research Program of the National Human Genome Research Institute (NHGRI) has released a new request for Applications (RFA) inviting Specialized Center (P50) and Exploratory (P20) grant applications for the development of Centers of Excellence in ELSI Research (CEERs).

The CEER program is designed to support the development of research centers that will identify and investigate ELSI research questions that can best be approached through intensive and extended collaboration among investigators from multiple disciplines, using diverse methodologies. The investigators in a CEER will be encouraged to consider new ways to explore these questions, design innovative and efficient research projects, propose and disseminate health or social policy options based on Center research and, when feasible, facilitate policy development pertinent to a specific issue. Center applicants are particularly encouraged to identify cutting edge research topics and approaches that have the possibility of leading to high payoff solutions to important ELSI problems.

Letters of intent are due on October 27, 2003. Applications are due November 24, 2003. Applicants are strongly encouraged to contact NHGRI ELSI staff prior to submitting an application. The complete CEER announcement is available online at: <http://grants1.nih.gov/grants/guide/rfa-files/RFA-HG-03-005.html>

(Information on other ELSI funding opportunities is available on the ELSI Program Research Funding Opportunities website: <http://www.genome.gov/page.cfm?pageID=10000930>.)

REDUCING DISPARITIES IN THE TREATMENT OF EPILEPSY

(PAS-03-164)

National Institute of Neurological Disorders and Stroke, National Institutes of Health
<http://grants.nih.gov/grants/guide/pa-files/PAS-03-164.html>

NIH ANNOUNCEMENTS:

BREAKING NEWS: CREATION OF NEW NEURONS CRITICAL TO ANTIDEPRESSANT ACTION IN MICE

<http://www.nimh.nih.gov/events/prneurogenesis.cfm>

STORY C. LANDIS, PH.D., NAMED NEW DIRECTOR OF THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

http://www.ninds.nih.gov/news_and_events/pressrelease_landis_080603.htm

NEWLY IDENTIFIED TUMOR SUPPRESSOR COOPERATES WITH P53 TO PROTECT MICE AGAINST TUMORS

<http://www.cancer.gov>

RESEARCH RESOURCES:

COOPERATIVE HUMAN TISSUE NETWORK

The Cooperative Human Tissue Network (CHTN) is supported by the National Cancer Institute to provide biomedical researchers with access to human tissues. Six member institutions coordinate the collection and distribution of tissues across the US and Canada in [six regional divisions](#). The CHTN specializes in the prospective procurement, preservation and distribution of human tissues for research. In addition to normal, benign and malignant tissues, tissues from patients with specific diseases such as ulcerative colitis, a premalignant state, are provided. Trained personnel coordinate the retrieval, preservation and delivery of specimens obtained from surgical resections and from autopsies. <http://www-chn.ims.nci.nih.gov/>

ANIMAL MODELS

Find national and international activities and major resources that are being developed to facilitate biomedical research using animal models. For organisms not listed, web pages may be developed in the future. <http://www.nih.gov/science/models/>

PROTEIN STRUCTURE AND FUNCTION LINKS

http://www.sciencemag.org/feature/plus/sfg/resources/res_protein.shtml#data

PROTEOMICS LINKS

http://www.sciencemag.org/feature/plus/sfg/resources/res_proteomics.shtml

SIGNAL TRANSDUCTION KNOWLEDGE ENVIRONMENT – INFORMATION AND LINKS

<http://stke.sciencemag.org/>

LINKS TO TSC RESEARCH RESOURCES

<http://www.childhooddiseases.org/rsc.html>

TSC TISSUE AVAILABILITY:

If you are a health care professional, and one of your patients with TSC will undergo surgery, please encourage them to donate the tissue removed at the time of surgery for research. This tissue is critical to the research efforts to understand the function(s) of the TSC genes and their protein products tuberin and hamartin, as well as for the development of new treatments and

therapies. Individuals with TSC and their families may contact the TS Alliance for additional information about tissue donation. Tissues obtained at the time of death are also needed, but careful coordination is needed so that the tissue can be obtained as soon as possible after the time of death so that it is viable for research efforts.

The following tissues from individuals with TSC have been received (or will be received in the near future) by the Maryland Brain and Tissue Bank:

- Tuber
- Renal angiomyolipoma

Please contact the Brain and Tissue Bank if you are interested in obtaining any of this tissue for your research. You may contact them by phone at: 1-800-847-1539 or via e-mail at btbumab@umaryland.edu. Additional information can be found on their website at: <http://som1.umaryland.edu/BTBank/main.html>

CLINICAL TRIALS/STUDIES:

NHLBI: LYMPHANGIOLEIOMYOMATOSIS (LAM) PROTOCOL

This study is being conducted by Dr. Joel Moss at the National Heart, Lung and Blood Institute at the National Institutes of Health. Dr. Moss is recruiting women with TSC, whether or not they have been diagnosed with LAM, as well as women with LAM. His preliminary studies have shown that more than 40% of women with TSC have LAM, although most will be asymptomatic, so he is interested in recruiting more women with TSC.

The protocol includes an initial 4 day admission for inpatient studies involving a general medical evaluation, as well as other routine pulmonary function testing. The women are asked to return for repeat studies every six months for five years. Any part(s) of the testing may be declined by the participant.

Any woman with TSC who participates in this study will continue to remain under the care of her own physician. After each visit, a summary of the evaluation findings will be sent to her physician. There is no charge for the evaluation. In addition, under most circumstances, transportation expenses will be paid for patients living in the United States and Canada. Women in other countries may participate if they are willing to pay their own expenses and commit to returning every year.

The Tuberous Sclerosis Alliance encourages women with TSC and physicians who have patients with TSC, whether or not they have been diagnosed with LAM, to participate in this worthwhile study. Studies such as this are the first step in understanding this devastating disease and we are fortunate that the NHLBI has initiated a protocol aimed at understanding the pathogenesis of LAM. Success of the program will depend on their ability to recruit participants for the study. If you are interested in further information or have any questions, you may contact NHLBI at 1-877-NIH-LUNG (1-877-644-5864). Choose # 3 from the menu items after dialing. This is a toll free number.

RAPAMYCIN CLINICAL TRIAL FOR RENAL AND LUNG INVOLVEMENT IN TSC AND LAM

Contact: Frank McCormack at frank.mccormack@uc.edu; or 513-558-4831, John Bissler at john.bissler@chmcc.org, or David Franz at david.franz@chmcc.org.

NEW TSC PUBLICATIONS:

TSC RESEARCH SPOTLIGHT:

Wong M, Ess KC, Uhlmann EJ, Jansen LA, Li W, Crino PB, Mennerick S, Yamada KA, Gutmann DH (2003) Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. *Ann Neurol* 54(2):251-6

Excessive astrocytosis in cortical tubers in tuberous sclerosis complex (TSC) suggests that astrocytes may be important for epileptogenesis in TSC. Uhlmann and coworkers (2002) previously demonstrated that astrocyte-specific Tsc1 gene inactivation in mice (Tsc1 cKO mice) results in progressive epilepsy. Wong et al. (2003) report that glutamate transporter expression and function is impaired in Tsc1 cKO astrocytes. Tsc1 cKO mice exhibit decreased GLT-1 and GLAST protein expression. Electrophysiological assays demonstrate a functional decrease in glutamate transport currents of Tsc1 cKO astrocytes in hippocampal slices and astrocyte cultures. These findings suggest that Tsc1 inactivation in astrocytes causes dysfunctional glutamate homeostasis, leading to seizure development in TSC.

NEW PUBLICATIONS:

Balasubramanian S, Kuppaswamy D (2003) RGD-containing peptides activate S6K1 through beta 3 integrin in adult cardiac muscle cells. *J Biol Chem*. 2003 Aug 9 [Epub ahead of print]
<http://www.jbc.org/cgi/reprint/M303428200v1>

Beltle J, Seemann MD (2003) Computed tomographic findings in bourneville-pringle disease. *Eur J Med Res* 8(7):292-4

Chan AL, Kwack S, Jones KD, Glassberg MK, Gherman CR (2003) Lymphangioleiomyomatosis and SZ alpha(1)-Antitrypsin Disease: A Unique Combination? *Chest* 124(2):763-5

Dancey JE (2002) Clinical development of mammalian target of rapamycin inhibitors. *Hematol Oncol Clin North Am* 16(5):1101-14

Dimmler A, Seitz G, Hohenberger W, Kirchner T, Faller (2003) Late pulmonary metastasis in uterine PEComa. *J Clin Pathol* 56(8):627-8

Hancock E, Osborne J, Milner P (2003) Treatment of infantile spasms. *Cochrane Database Syst Rev* (3):CD001770

Hengstschlager M, Rosner M, Fountoulakis M, Lubec (2003) Regulation of PCNA and CAF-1 expression by the two tuberous sclerosis gene products. *Biochem Biophys Res Commun* 307(3):737-42

Honda S, Kobayashi T, Kajino K, Urakami S, Igawa M, Hino O (2003) Ets protein Elf-1 bidirectionally suppresses transcriptional activities of the tumor suppressor Tsc2 gene and the repair-related Nth1 gene. *Mol Carcinog*. 37(3):122-9

Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. *Curr Opin Pharmacol* 3(4):371-7

Lau SK, Marchevsky AM, McKenna RJ Jr, Luthringer DJ (2003) Malignant monotypic epithelioid angiomyolipoma of the retroperitoneum. *Int J Surg Pathol* 11(3):223-8

- Lin WC, Wang JH, Wei CJ, Pan CC, Chang CY (2003) Malignant renal epithelioid angiomyolipoma with aggressive behavior and distant metastasis. *J Chin Med Assoc* 66(5):303-6
- Lizcano JM, Alrubaie S, Kieloch A, Deak M, Leever SJ, Alessi D (2003) Insulin-induced *Drosophila* S6 kinase activation requires Phosphoinositide 3-kinase and Protein kinase B. *Biochem J* 2003 Jul 4 [Epub ahead of print] <http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20030577.htm>
- Marangi M, Zechini B, Fileti A, Quaranta G, Aceti A (2003) *Hymenolepis diminuta* Infection in a Child Living in the Urban Area of Rome, Italy. *J Clin Microbiol* 41(8):3994-5
- Miyake T, Hiraishi H, Sammoto H, Ono B (2003) Involvement of the VDE homing endonuclease and rapamycin in regulation of the *Saccharomyces cerevisiae* GSH11 gene encoding the high-affinity glutathione transporter. *J Biol Chem* Aug 4 [Epub ahead of print] <http://www.jbc.org/cgi/reprint/M302084200v1>
- O'Connor SE, Kwiatkowski DJ, Roberts PS, Wollmann RL, Huttenlocher PR (2003) A family with seizures and minor features of tuberous sclerosis and a novel TSC2 mutation. *Neurology* 61(3):409-12
- Panka DJ, Mier JW (2003) Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in Endothelial cells. *J Biol Chem*. 2003 Jul 22 [Epub ahead of print]. <http://www.jbc.org/cgi/reprint/M307339200v1>
- Papaioannou EG, Staikou CV, Lambadarioui A, Karavokyros IG, Tsinari K (2003) Anesthetic management of a patient with tuberous sclerosis presenting for renal transplantation. *J Anesth* 17(3):193-5
- Parkington JD, Siebert AP, LeBrasseur NK, Fielding RA (2003) Differential activation of mTOR signaling by contractile activity in skeletal muscle. *Am J Physiol Regul Integr Comp Physiol*. 2003 Jul 24 [Epub ahead of print] <http://ajpregu.physiology.org/cgi/reprint/00324.2003v1>
- Patel PH, Thapar N, Guo L, Martinez M, Maris J, Gau CL, Lengyel JA, Tamanoi F (2003) *Drosophila* Rheb GTPase is required for cell cycle progression and cell growth. *J Cell Sci* 116(Pt 17):3601-10
- Pelz J, Weber K, Gohl J, Dimmler A, Hohenberger W (2003) [Angiomyolipoma of the colon - case report and review of the literature.] *Z Gastroenterol* 41(8):715-8 [Article in German]
- Punt CJ, Boni J, Brunsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. *Ann Oncol* 14(6):931-7
- Rosner M, Hofer K, Kubista M, Hengstschlager M (2003) Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. *Oncogene* 22(31):4786-98
- Shiono J, Horigome H, Yasui S, Miyamoto T, Takahashi-Igari M, Iwasaki N, Matsui A (2003) Electrocardiographic changes in patients with cardiac rhabdomyomas associated with tuberous sclerosis. *Cardiol Young* 13(3):258-63
- Shitrit D, Izbicki G, Ben-Dov I, Kramer MR (2003) Lymphangioliomyomatosis: a rare indication for lung transplantation. *Isr Med Assoc J* 5(7):533

Sironi M, Spinelli M (2003) Oncocytic angiomyolipoma of the kidney: a case report. *Int J Surg Pathol* 11(3):229-34

Song K, Cornelius SC, Reiss M, Danielpour D (2003) IGF-I inhibits transcriptional responses of TGF-beta by PI3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. *J Biol Chem* 2003 Jul 21 [Epub ahead of print]. <http://www.jbc.org/cgi/reprint/M304583200v1>

Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb. *Curr Biol* 13(15):1259-68

Trauner MA, Ruben BS, Lynch PJ (2003) Segmental tuberous sclerosis presenting as unilateral facial angiofibromas. *J Am Acad Dermatol* 49(2 Suppl Case Reports):S164-6

Tworetzky W, McElhinney DB, Margossian R, Moon-Grady AJ, Sallee D, Goldmuntz E, van der Velde ME, Silverman NH, Allan LD (2003) Association between cardiac tumors and tuberous sclerosis in the fetus and neonate. *Am J Cardiol* 92(4):487-9

Whang YE, Godley PA (2003) Renal cell carcinoma. *Curr Opin Oncol* 15(3):213-6

Wong M, Ess KC, Uhlmann EJ, Jansen LA, Li W, Crino PB, Mennerick S, Yamada KA, Gutmann DH (2003) Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. *Ann Neurol* 54(2):251-6

LEGISLATIVE UPDATE:

SUPPORT A CRITICAL AMENDMENT TO INCREASE NIH FUNDING IN FY 2004

The Tuberous Sclerosis Alliance urges you to contact your Senators to ask them to support an amendment, sponsored by Senators Arlen Specter and Tom Harkin, which would increase funding at the National Institutes of Health (NIH) by \$2.5 billion for FY 2004. The Senate Appropriations committee provided a 3.7% increase when it considered the NIH funding bill last month. This small increase also contained language reducing the amount available for grants. The full House approved a bill providing NIH with only a 2.5% increase.

Senate Labor-HHS-Education Subcommittee Chair Arlen Specter (R-PA) and Ranking Member Tom Harkin (D-IA) will be offering an amendment to the NIH bill during the full Senate consideration that would increase NIH funding by \$1.5 billion over the level the Senate Appropriations committee approved, bringing the total NIH increase to \$2.5 billion, a 9.2% increase over FY 2003. Because this amendment would violate a spending cap imposed in the FY 2004 budget resolution, it will require 60 votes to pass--so contact your Senators today.

Suggested text for e-mail to Senators (please cut and paste and send to your Senators):

I am writing to you to encourage you to support the amendment to the NIH appropriations bill that will be offered by Senators Arlen Specter (R-PA) and Tom Harkin (D-IA) during the full Senate consideration. This amendment would increase NIH funding by \$1.5 billion over the level the Senate Appropriations committee approved, bringing the total NIH increase to \$2.5 billion, a 9.2% increase over FY 2003. This funding is critical to maintaining the momentum of medical research in the United States so that new treatments and therapies can be developed for individuals with diseases ranging from the very rare to the very common. **[Briefly discuss your TSC research and other research that might be affected by this increase, or negatively**

impacted if there is only a 2.5% increase in the NIH budget.] I thank you for your consideration of this request, and hope to see that you voted in favor of this amendment.

Sincerely,
Dr. XXXX

Go to: <http://www.senate.gov> to find the e-mail contact forms for your Senators.

NEWS:

TSC CLINIC OPENS AT LOMA LINDA UNIVERSITY

The Tuberous Sclerosis Alliance is pleased to announce the opening of the Loma Linda University Health Care Tuberous Sclerosis Clinic. Under the direction of Dr. Stephen Ashwal, the clinic is dedicated to providing proactive medical care for patients with tuberous sclerosis complex (TSC).

With few exceptions, the clinic is currently seeing patients on the second Thursday and fourth Wednesday of each month. For more information, or to schedule an appointment, please call the clinic's nurse coordinator, Teresa Serna, at (909) 558-2383.

NEW TS ALLIANCE FACT SHEET ON INFANTILE SPASMS IN TSC NOW AVAILABLE

The Tuberous Sclerosis Alliance announces the completion of a new Fact Sheet on Infantile Spasms in TSC. This Fact Sheet contains important information for both parents of children with TSC and health care providers. The Fact Sheet will be available on the TS Alliance website soon at <http://www.tsalliance.org> or contact the organization to obtain a copy of the Fact Sheet at: 1-800-225-6872 or info@tsalliance.org

CONFERENCES:

For a complete listing of conferences, visit the TS Alliance website at:
<http://216.33.101.121/Research/upcoming%20conferences.asp>

October 1, 2003

Tuberous Sclerosis Complex Symposium

Satellite Conference in conjunction with the Child Neurology Society Meeting

Sponsored by the TS Alliance, NINDS, NIH and CNS

Loews Miami Beach Hotel, Miami Beach, FL

Advance registration REQUIRED: You must register on-line or by FAX/mail on or before September 15, 2003. Limited to first 250 registrants.

http://www.childneurologysociety.org/events/evt_001.asp

October 22-25, 2003

National Association for the Dually Diagnosed Annual Conference

Holiday Inn – Chicago Mart Plaza, Chicago, IL

<http://www.thenadd.org/content/conferences/20thannualspk.shtml>

March 26-28, 2004

LAM Foundation Research Conference

The Westin, Downtown Cincinnati, OH

More information coming soon!

Save the date!!! September 16-18, 2004

Tuberous Sclerosis Association International Research Conference

Queens College, Cambridge UK

(More information coming soon!)

ARCHIVED ISSUES OF TSC ALERT:

December 2002 TSC Alert

<http://www.tsalliance.org/research/tsc%20alert.asp>

January 2003 TSC Alert

<http://www.tsalliance.org/Research/TSC%20Alert012203.asp>

February 2003 TSC Alert

<http://www.tsalliance.org/Research/TSC%20Alert021003.asp>

March 2003 TSC Alert

<http://www.tsalliance.org/Research/TSC%20Alert030403.asp>

April 2003 TSC Alert

<http://www.tsalliance.org/Research/TSC%20Alert040103.asp>

May 2003 TSC Alert

<http://www.tsalliance.org/Research/TSC%20Alertdefault.asp>

June 2003 TSC Alert

<http://www.tsalliance.org/Research/TSC%20Alert060103.asp>

July 2003 TSC Alert

<http://www.tsalliance.org/Research/TSC%20Alertdefault.asp>